Advertisement
Organisation › Details
Gimv (Group)
Gimv is a European investment company, listed on Euronext Brussels, with 40 years' experience in private equity and venture capital. The company currently has a portfolio of EUR 1.2 billion of investments in around 50 portfolio companies, with combined turnover of EUR 2.5 billion and 14,000 employees. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv's four investment platforms are Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. *
Start | 2004-04-01 existent | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Street | 37 Karel Oomsstraat | |
City | 2018 Antwerpen | |
Tel | +32-3-290-2100 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 1,200,000,000 (invested (2020) 2020-11-19) | |
Profit | 137,200,000 (2016-03-31) | |
* Document for »About Section«: SynOx Therapeutics Ltd.. (11/19/20). "Press Release: SynOx Therapeutics Raises €37M in Series A Financing. HealthCap and Medicxi Co-lead, Joined by Forbion and Gimv". Dublin. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Gimv (Group)
- [1] Complement Therapeutics GmbH. (4/17/23). "Press Release: Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases". Munich....
- [2] Gimv. (6/15/22). "Press Release: Gimv Strengthens Its Position in Life Sciences Venture Capital with the Creation of a New Dedicated Platform". Antwerp....
- [3] SynOx Therapeutics Ltd.. (11/19/20). "Press Release: SynOx Therapeutics Raises €37M in Series A Financing. HealthCap and Medicxi Co-lead, Joined by Forbion and Gimv". Dublin....
- [4] Wellington Partners. (1/8/20). "Press Release: Karl Naegler Joins Wellington Partners as Managing Partner". Munich....
- [5] Gimv. (5/2/17). "Press Release: Gimv Invests in Emerging Immuno-oncology Company ImCheck Therapeutics". Antwerp & Marseille....
- [6] Breath Therapeutics Holding B.V.. (3/8/17). "Press Release: Breath Therapeutics Raises EUR 43.5 Million in Series A Financing". Munich, Antwerp, Paris & Utrecht....
- [7] Gimv. (3/8/17). "Press Release: Gimv Co-leads EUR 43.5 million Financing of Breath Therapeutics". Antwerp....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top